This review aimed to furnish clinicians with the latest clinical outcomes associated with apixaban and vitamin K antagonists (VKAs) in managing AF patients on dialysis. Methods: Literature from the PubMed and Embase databases up to March 2024 underwent systematic scrutiny for inclusion. ...
Since the discovery of vitamin K antagonists in the early 1940s, there has been little change in anticoagulation until, in the 1990s, widespread use of low... JC Zikria,J Ansell - 《Current Opinion in Hematology》 被引量: 100发表: 2009年 Management and clinical outcomes in patients treated...
Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Ukaigwe A,Shrestha P,Karmacharya P,et al. J Interv Card Electrophy-siol . 2017...
Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis Non-vitamin K oral anticoagulants (NOACs) are being increasingly prescribed. These drugs act rapidly, have predictable dose-related anticoagulation effect ... B Abdulhadi,R Mulki,A Goyal,... - 《Bmj Case Rep...
Apixaban (Eliquis) is the only non-vitamin K antagonist oral anticoagulant (NOAC) but warfarin (Coumadin) is a Vitamin K antagonist anticoagulant (VKA) (source). What foods should I avoid while on Eliquis? As stated onDrugwatch.com, Eliquis has no food-drug restrictions and does not interact...
Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism Arterial and venous thromboembolic diseases are a clinical and economic burden worldwide. In addition to traditional agents such as vitamin K antagonists a... AG Turpie ...
Introduction:Left ventricular thrombus (LVT), a major complication following acute myocardial infarction, significantly contributes to the increased risk of stroke and systemic embolism. Although vitamin K antagonists (VKAs) are the first-line treatment for LVT, direct oral anticoagulants (DOACs) have ...
Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort StudyIntroduction Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events....
W. Frank Peacock MD bMatthias Antz MD cHeart, Lung and CirculationColeman CI, Peacock WF, Antz M. Comparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practice. Heart Lung Circ. Epub 2017 May ...
Apixaban, a non-vitamin K oral anticoagulant (NOAC), has demonstrated better efficacy and safety characteristics than the VKA warfarin in the ARISTOTLE trial. This study aims to quantify the potential societal effects of using apixaban instead of VKA in the German NVAF population from 2017 to ...